Radiopharm Theranostics Limited

CHIA:RAD Stock Report

Market Cap: AU$52.2m

Radiopharm Theranostics Valuation

Is RAD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RAD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RAD (A$0.02) is trading below our estimate of fair value (A$1.97)

Significantly Below Fair Value: RAD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RAD?

Key metric: As RAD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RAD. This is calculated by dividing RAD's market cap by their current revenue.
What is RAD's PS Ratio?
PS Ratio26.6x
SalesAU$1.96m
Market CapAU$52.15m

Price to Sales Ratio vs Peers

How does RAD's PS Ratio compare to its peers?

The above table shows the PS ratio for RAD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.6x
ACW Actinogen Medical
7.7x20.0%AU$76.8m
PTX Prescient Therapeutics
10.6xn/aAU$39.5m
ATX Amplia Therapeutics
8.5xn/aAU$29.1m
BDX BCAL Diagnostics
11.5x77.6%AU$35.5m
RAD Radiopharm Theranostics
26.6x50.2%AU$52.2m

Price-To-Sales vs Peers: RAD is expensive based on its Price-To-Sales Ratio (26.6x) compared to the peer average (9.6x).

Price to Sales Ratio vs Industry

How does RAD's PS Ratio compare vs other companies in the AU Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
ARX Aroa Biosurgery
3.4x21.3%US$146.45m
IMC Immuron
3.7x59.7%US$11.45m
BNO Bionomics
2.4x-5.3%US$9.52m
CHM Chimeric Therapeutics
0.9xn/aUS$4.35m
RAD 26.6xIndustry Avg. 10.0xNo. of Companies8PS01632486480+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: RAD is expensive based on its Price-To-Sales Ratio (26.6x) compared to the Australian Biotechs industry average (10x).

Price to Sales Ratio vs Fair Ratio

What is RAD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RAD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio26.6x
Fair PS Ratio0.01x

Price-To-Sales vs Fair Ratio: RAD is expensive based on its Price-To-Sales Ratio (26.6x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RAD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.025
AU$0.24
+883.6%
55.4%AU$0.40AU$0.073n/a3
Dec ’25AU$0.029
AU$0.24
+730.9%
55.4%AU$0.40AU$0.073n/a3
Nov ’25AU$0.024
AU$0.25
+953.9%
53.6%AU$0.40AU$0.073n/a3
Oct ’25AU$0.028
AU$0.25
+793.0%
47.3%AU$0.40AU$0.07n/a4
Sep ’25AU$0.035
AU$0.44
+1,147.5%
53.0%AU$0.76AU$0.26n/a3
Aug ’25AU$0.035
AU$0.50
+1,334.7%
39.9%AU$0.75AU$0.26n/a3
Jul ’25AU$0.038
AU$0.50
+1,221.4%
39.9%AU$0.75AU$0.26n/a3
Jun ’25AU$0.032
AU$0.38
+1,090.2%
31.6%AU$0.50AU$0.26n/a2
May ’25AU$0.044
AU$0.48
+990.8%
45.7%AU$0.70AU$0.26n/a2
Apr ’25AU$0.06
AU$0.48
+699.9%
45.7%AU$0.70AU$0.26n/a2
Jan ’25AU$0.072
AU$0.47
+550.7%
47.5%AU$0.69AU$0.25n/a2
Dec ’24AU$0.074
AU$0.48
+547.6%
46.2%AU$0.70AU$0.26AU$0.0292
Nov ’24AU$0.083
AU$0.48
+477.4%
46.2%AU$0.70AU$0.26AU$0.0242
Oct ’24AU$0.13
AU$0.48
+283.1%
46.3%AU$0.70AU$0.26AU$0.0282
Sep ’24AU$0.098
AU$0.47
+384.3%
47.8%AU$0.70AU$0.25AU$0.0352
Aug ’24AU$0.095
AU$0.47
+399.6%
47.8%AU$0.70AU$0.25AU$0.0352
Jul ’24AU$0.11
AU$0.47
+331.5%
47.8%AU$0.70AU$0.25AU$0.0382
Jun ’24AU$0.14
AU$0.50
+271.3%
50.2%AU$0.75AU$0.25AU$0.0322
May ’24AU$0.20
AU$0.50
+151.3%
49.8%AU$0.75AU$0.25AU$0.0442
Apr ’24AU$0.17
AU$0.50
+204.6%
49.8%AU$0.75AU$0.25AU$0.062

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 01:19
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Radiopharm Theranostics Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Hunter DiamondDiamond Equity Research LLC
Justin WalshJonesTrading Institutional Services, LLC